# EMPagliflozin After Aortic Valve Replacement

> **NCT06171802** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 205 (estimated)

## Conditions studied

- Aortic Valve Stenosis

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06171802
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-14
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06171802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06171802, "EMPagliflozin After Aortic Valve Replacement". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06171802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*